|
US 11,918,607 B2 |
|
| Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers |
| Heiko Schuster, Tuebingen (DE); Franziska Hoffgaard, Tuebingen (DE); Jens Fritsche, Dusslingen (DE); Oliver Schoor, Tuebingen (DE); Toni Weinschenk, Aichwald (DE); Daniel Johannes Kowalewski, Kirchentellinsfurt (DE); and Chih-Chiang Tsou, Pearland, TX (US) |
| Assigned to IMMATICS BIOTECHNOLOGIES GMBH, Tuebingen (DE) |
| Filed by Immatics Biotechnologies GmbH, Tuebingen (DE) |
| Filed on Jul. 16, 2021, as Appl. No. 17/377,724. |
| Application 17/377,724 is a continuation of application No. 17/155,960, filed on Jan. 22, 2021, granted, now 11,779,606. |
| Application 17/155,960 is a continuation of application No. 16/914,073, filed on Jun. 26, 2020, granted, now 11,020,433, issued on Jun. 1, 2021. |
| Application 16/914,073 is a continuation of application No. 16/659,256, filed on Oct. 21, 2019, granted, now 10,695,373, issued on Jun. 30, 2020. |
| Application 16/659,256 is a continuation of application No. 16/274,505, filed on Feb. 13, 2019, granted, now 10,993,962, issued on May 4, 2021. |
| Claims priority of provisional application 62/633,325, filed on Feb. 21, 2018. |
| Claims priority of application No. 10 2018 103 944 (DE), filed on Feb. 21, 2018; and application No. 10 2018 107 224 (DE), filed on Mar. 27, 2018. |
| Prior Publication US 2021/0338734 A1, Nov. 4, 2021 |
| This patent is subject to a terminal disclaimer. |
| Int. Cl. A61K 39/00 (2006.01); A61K 35/17 (2015.01); A61K 38/08 (2019.01); A61K 39/12 (2006.01); A61K 39/39 (2006.01); A61K 39/395 (2006.01); A61K 45/06 (2006.01); A61P 35/00 (2006.01); A61P 35/02 (2006.01); C07K 7/06 (2006.01); C07K 14/47 (2006.01); C07K 14/54 (2006.01); C07K 16/24 (2006.01); C07K 16/28 (2006.01); C12N 5/0783 (2010.01); A61K 45/00 (2006.01) |